| Updated results from MONALEESA-2, a phase III trial of first-line ribociclib plus letrozole versus placebo plus letrozole in hormone receptor-positive, HER2-negative advanced … GN Hortobagyi, SM Stemmer, HA Burris, YS Yap, GS Sonke, ... Annals of Oncology 29 (7), 1541-1547, 2018 | 803 | 2018 |
| Effect of P-glycoprotein (P-gp) inducers on exposure of P-gp substrates: review of clinical drug–drug interaction studies M Elmeliegy, M Vourvahis, C Guo, DD Wang Clinical pharmacokinetics 59, 699-714, 2020 | 218 | 2020 |
| Elranatamab in relapsed or refractory multiple myeloma: phase 2 MagnetisMM-3 trial results AM Lesokhin, MH Tomasson, B Arnulf, NJ Bahlis, H Miles Prince, ... Nature medicine 29 (9), 2259-2267, 2023 | 164 | 2023 |
| Role of ATP-binding cassette and solute carrier transporters in erlotinib CNS penetration and intracellular accumulation MA Elmeliegy, AM Carcaboso, M Tagen, F Bai, CF Stewart Clinical Cancer Research 17 (1), 89-99, 2011 | 117 | 2011 |
| Tyrosine kinase inhibitor gefitinib enhances topotecan penetration of gliomas AM Carcaboso, MA Elmeliegy, J Shen, SJ Juel, ZM Zhang, C Calabrese, ... Cancer research 70 (11), 4499-4508, 2010 | 89 | 2010 |
| Talazoparib in Patients with a Germline BRCA‐Mutated Advanced Breast Cancer: Detailed Safety Analyses from the Phase III EMBRACA Trial SA Hurvitz, A Gonçalves, HS Rugo, KH Lee, L Fehrenbacher, LA Mina, ... The oncologist 25 (3), e439-e450, 2020 | 81 | 2020 |
| Phase I study of the prolactin receptor antagonist LFA102 in metastatic breast and castration-resistant prostate cancer N Agarwal, JP Machiels, C Suárez, N Lewis, M Higgins, K Wisinski, ... The oncologist 21 (5), 535-536i, 2016 | 74 | 2016 |
| Compartment-specific roles of ATP-binding cassette transporters define differential topotecan distribution in brain parenchyma and cerebrospinal fluid J Shen, AM Carcaboso, KE Hubbard, M Tagen, HG Wynn, JC Panetta, ... Cancer research 69 (14), 5885-5892, 2009 | 69 | 2009 |
| Ribociclib Bioavailability Is Not Affected by Gastric pH Changes or Food Intake: In Silico and Clinical Evaluations TS Samant, S Dhuria, Y Lu, M Laisney, S Yang, A Grandeury, ... Clinical Pharmacology & Therapeutics 104 (2), 374-383, 2018 | 67 | 2018 |
| Pazopanib exposure relationship with clinical efficacy and safety in the adjuvant treatment of advanced renal cell carcinoma CN Sternberg, F Donskov, NB Haas, C Doehn, P Russo, M Elmeliegy, ... Clinical Cancer Research 24 (13), 3005-3013, 2018 | 62 | 2018 |
| Talazoparib plus enzalutamide in metastatic castration-resistant prostate cancer: TALAPRO-2 phase III study design N Agarwal, A Azad, ND Shore, J Carles, AP Fay, C Dunshee, LI Karsh, ... Future Oncology 18 (4), 425-436, 2022 | 40 | 2022 |
| Discordance between child‐pugh and national cancer institute classifications for hepatic dysfunction: implications on dosing recommendations for oncology compounds M Elmeliegy, DZ Yang, E Salama, K Parivar, DD Wang The Journal of Clinical Pharmacology 61 (1), 105-115, 2021 | 30 | 2021 |
| Ribociclib drug‐drug interactions: Clinical evaluations and physiologically‐based pharmacokinetic modeling to guide drug labeling TS Samant, F Huth, K Umehara, H Schiller, SV Dhuria, M Elmeliegy, ... Clinical Pharmacology & Therapeutics 108 (3), 575-585, 2020 | 25 | 2020 |
| Evaluation of the effect of P‐glycoprotein inhibition and induction on talazoparib disposition in patients with advanced solid tumours M Elmeliegy, I Láng, EA Smolyarchuk, CH Chung, A Plotka, H Shi, ... British Journal of Clinical Pharmacology 86 (4), 771-778, 2020 | 24 | 2020 |
| Efficacy and safety of elranatamab in patients with relapsed/refractory multiple myeloma (RRMM) and prior B-cell maturation antigen (BCMA)-directed therapies: A pooled analysis … AK Nooka, AM Lesokhin, M Mohty, R Niesvizky, C Maisel, B Arnulf, ... Journal of Clinical Oncology 41 (16_suppl), 8008-8008, 2023 | 20 | 2023 |
| Considerations on the calculation of the human equivalent dose from toxicology studies for biologic anticancer agents M Elmeliegy, C Udata, K Liao, D Yin Clinical Pharmacokinetics 60, 563-567, 2021 | 20 | 2021 |
| Clinical and safety outcomes of TALAPRO-2: A two-part phase III study of talazoparib (TALA) in combination with enzalutamide (ENZA) in metastatic castration-resistant prostate … N Agarwal, ND Shore, C Dunshee, LI Karsh, B Sullivan, N Di Santo, ... Journal of Clinical Oncology 37 (15_suppl), 5076-5076, 2019 | 17 | 2019 |
| Magnetic resonance imaging–guided microdialysis cannula implantation in a spontaneous high-grade glioma murine model MA Elmeliegy, AM Carcaboso, LML Chow, ZM Zhang, C Calabrese, ... Journal of pharmaceutical sciences 100 (10), 4210-4214, 2011 | 16 | 2011 |
| Exposure‐Safety Analyses of Talazoparib in Patients With Advanced Breast Cancer and Germline BRCA1/2 Mutations in the EMBRACA and ABRAZO Trials M Elmeliegy, Y Yu, JK Litton, A Czibere, GG Wilson, IC Tudor, J Zheng, ... The Journal of Clinical Pharmacology 60 (10), 1334-1343, 2020 | 12 | 2020 |
| Talazoparib Exposure‐Efficacy Analysis in Patients With Advanced Breast Cancer and Germline BRCA1/2 Mutations in the EMBRACA Trial Y Yu, M Elmeliegy, JK Litton, IC Tudor, A Czibere, J Zheng, DD Wang The Journal of Clinical Pharmacology 60 (10), 1324-1333, 2020 | 12 | 2020 |
